{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"15.1","upperLimit":"24.5","value":"19.5"},{"groupId":"OG001","lowerLimit":"9.1","upperLimit":"17.2","value":"12.8"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"292"},{"groupId":"OG001","value":"290"}],"units":"Participants"}],"description":"ORR was defined as the percentage of participants whose Best Overall Response (BOR) was a confirmed Complete Response (CR) or Partial Response (PR). BOR was defined as the best investigator-assessed response designation, recorded between the date of randomization and the date of objectively documented progression per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) or the date of subsequent anti-cancer therapy (excluding on-treatment palliative radiotherapy of non-target bone lesions or Central Nervous System (CNS) lesions), whichever occurred first. CR = Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \\< 10 mm. PR = At least a 30% decrease in the sum of diameters of target lesions, taking, as reference, the baseline sum diameters. CR+PR, confidence interval based on the Clopper and Pearson method.","dispersionType":"95% Confidence Interval","groups":[{"description":"Nivolumab 3 mg/kg solution administered intravenously every 2 weeks. Eligible participants transitioned to nivolumab 480 mg every 4 weeks. Participants treated until disease progression, discontinuation due to toxicity, withdrawal of consent or end of study.","id":"OG000","title":"Nivolumab"},{"description":"Docetaxel 75mg/m\\^2 solution administered intravenously every 3 weeks. Eligible participants transitioned to nivolumab 3 mg/kg every 2 weeks or 480 mg every 4 weeks. Participants treated until disease progression, discontinuation due to toxicity, withdrawal of consent or end of study.","id":"OG001","title":"Docetaxel"}],"paramType":"NUMBER","populationDescription":"All randomized participants","reportingStatus":"POSTED","timeFrame":"From randomization to date of objectively documented progression (up to approximately 110 months)","title":"Objective Response Rate (ORR)","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}